Plasma-Derived Extracellular Vesicles as Potential Biomarkers in Heart Transplant Patient with Chronic Chagas Disease by Cortés Serra, Núria et al.
Chagas disease, caused by Trypanosoma cruzi para-site, is one of the most prevalent parasitic infec-
tions in Latin America and is responsible for millions 
of clinical cases. However, mainly because of migra-
tory movements, the epidemiology of Chagas disease 
has changed in recent decades; cases have increased 
substantially in North America, Europe, and Asia, 
where it is not endemic (1). Thus, raising awareness 
of this debilitating or deadly neglected tropical dis-
ease and promoting the creation of global strategies 
for its accurate diagnosis, treatment, and control are 
of paramount importance.
Detection of T. cruzi–specific antibodies in se-
rologic assays is the current standard technique 
for diagnosing chronic Chagas disease. However, 
this so-called conventional serology is not a valid 
indicator of chemotherapeutic outcomes because 
most patients remain seropositive for 10–20 years 
after treatment (2). Therefore, validated biomarkers 
are lacking for early assessment of therapeutic re-
sponses for testing current and new drugs or treat-
ment regimens.
Extracellular vesicles (EVs) are cell-derived mem-
branous nanoparticles present in most biologic fluids. 
Biofluid-derived EVs are minimally invasive molecu-
lar tools for diagnosing and screening diseases (3). 
They can be released by various mammalian cells and 
pathogens, and their use as predictive biomarkers for 
disease progression and treatment outcomes has been 
reported for different pathologic conditions, includ-
ing parasitic diseases (3,4).
The Study
The Ethical Committee of Clinical Research of 
Hospital Clinic (Barcelona, Spain; reference no. 
Reg. HCB/2015/0616) approved this project. The 
patient provided written informed consent before 
sample collection.
In 2009, a 51-year-old patient from Bolivia with a 
history of chronic Chagas disease, exhibiting severe 
organ involvement (chronic cardiomyopathy Kuschnir 
III and megacolon and megaesophagus degree IV) (5), 
was admitted to the International Health Department 
(Hospital Clinic, Barcelona). Serologic diagnosis for 
chronic Chagas disease was performed using 2 ELI-
SA kits (Ortho-Clinical Diagnostics, https://www.
orthoclinicaldiagnostics.com) and BioELISA Chagas 
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Chagas disease is emerging in countries to which it is 
not endemic. Biomarkers for earlier therapeutic response 
assessment in patients with chronic Chagas disease are 
needed. We profiled plasma-derived extracellular vesi-
cles from a heart transplant patient with chronic Chagas 
disease and showed the potential of this approach for dis-
covering such biomarkers.
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(Biokit, https://www.biokit.com). Together with 
clinical management of dysphagia and constipation, 
a pacemaker in the context of third-degree atrioven-
tricular block was implanted. In July 2015, an echocar-
diogram revealed iterative cardiac failure and severe 
ventricular dysfunction (ejection fraction 15%–20%). 
On November 28, 2015, the patient underwent heart 
transplantation without incident, and results of follow-
up endomyocardial biopsies showed no early signs of 
transplant rejection.
After transplantation and in the context of im-
munosuppression therapy (Table 1), quantitative PCR 
(qPCR) was performed weekly to detect T. cruzi in 
the blood (Tc-qPCR) (7). First benznidazole treatment 
was started when several consecutive and positive Tc-
qPCRs confirmed Chagas disease reactivation. Three 
weeks after benznidazole treatment, the Tc-qPCR be-
came negative. After completion of 80% of the treat-
ment, bronchopulmonary aspergillosis developed, 
and the benznidazole course was interrupted. The 
Tc-qPCR became positive and a second benznidazole 
course was initiated; this time the patient completed 
the initial prescribed dose without evidence of thera-
peutic failure based on Tc-qPCR results. Plasma sam-
ples for purification and characterization of EVs were 
collected before the first benznidazole treatment and 
just after the second course (Table 1). Unexpectedly, 
the patient died in August 2016 because of a late organ 
rejection. Therefore, samples at 6 and 12 months post-
treatment, already included in the approved protocol, 
were not collected.
To determine whether circulating EVs from this 
patient could have been used as predictive biomark-
ers to evaluate therapeutic response and disease 
outcome in the Chagas disease context, we collected 
pretreatment and posttreatment plasma samples, and 
EVs were enriched by size-exclusion chromatogra-
phy (SEC) and characterized as described (8) (Figure 
1, panel A). As negative controls, plasma samples 
from 2 healthy donors were also subjected to SEC. 
We characterized eluting EVs by bead-based assay 
and Nanoparticle Tracking Analysis (Figure 1, panels 
B, C). We pooled aliquots (100 µL) from SEC fractions 
7–10 and determined protein composition using 2D-
liquid chromatography–tandem mass spectrometry 
(2D-LC-MS/MS). In brief, samples were digested 
with trypsin and resulting peptides were resolved 
by high-pH reversed-phase peptide fractionation (9), 
followed by C18 reversed-phase nanoflow ultrahigh-
performance liquid chromatography coupled to a 
Q Exactive Plus Hybrid Quadrupole-Orbitrap Mass 
Spectrometer (QE Plus MS; Thermo Fisher Scientific, 
https://www.thermofisher.com), as described (10). 
Raw 2D-LC-MS/MS data were analyzed using Pro-
teome Discoverer version 2.1.1.21 software (Thermo 
Fisher Scientific), followed by Scaffold perSPECtives 
version 4.8.7 (Proteome Software; http://www.pro-
teomesoftware.com). A protein database with com-
bined human, T. cruzi, and potential contaminants 
was generated from UniProt (https://www.uniprot.
org). Using a false-discovery rate <1% and 1 unique 
peptide per protein, we identified 12 T. cruzi pro-
teins and 338 human proteins (Appendix, https://
wwwnc.cdc.gov/EID/article/26/8/19-1042-App1.
xlsx). However, when we applied the more strin-
gent criterion of >2 unique peptides per protein, we 
detected only 1 T. cruzi protein (i.e., pyruvate phos-
phate dikinase [PPDK]), and 288 human  proteins, of 
which we identified 19 only in pretreatment samples 
(Table 2). PPDK has been identified by proteomic 
 
Table 1. Timeline of heart transplant patient with chronic Chagas disease from initial diagnosis to last follow-up and death* 
Date Infection Observation, treatment, outcome 
2015 Aug Cytomegalovirus, detected by serology Diagnosed only by positive IgG serology, no active infection (no positive 
IgM serology). No treatment. 
2015 Aug Toxoplasmosis, detected by serology Diagnosed only by positive IgG serology, no active infection (no positive 
IgM serology). No treatment. 
2015 Nov  Heart transplantation on Nov. 28. Patient started with immunosuppressive 
therapy (tacrolimus, azathioprine, prednisone) until the end of follow-up. 
2016 Jan Chagas disease reactivation, detection 
by qPCR 
Pretreatment sample collected on Jan 28. Patient started BZN treatment 
(2.5 mg/kg, twice a day, 60 d) on Feb 3. 
2016 Mar Bronchopulmonary aspergillosis,  
detected by serology and CT 
BZN course interrupted on Mar 21. Completed 80% of the prescribed 
treatment. 
2016 Mar Bronchopulmonary aspergillosis Aspergillosis treatment started on Mar 22. Initially with voriconazole and 
amphotericin B liposomal. Treatment was changed to posaconazole until 
the end of the follow-up.† 
2016 Apr Chagas disease reactivation, detected 
by qPCR 
On Apr 14, patient started second round of BZN treatment until May 5, 
completing 100% of the prescribed treatment. 
2016 May  Posttreatment sample collected on May 11. 
2016 Aug  Late organ rejection. Patient died. 
*BZN, benznidazole; CT, computed tomographic scan; qPCR, quantitative PCR. 
†Parasite clearance could be related to the prolonged used of posaconazole, as previously reported (6), and/or the combined use of posaconazole and 
benznidazole because a second round of the latter was started in April 2016. 
 
Biomarkers for Chagas Disease
analysis of T. cruzi total secretome and EVs (10–12). 
This protein plays a central role in the metabolism 
of T. cruzi glycosomes and has been shown to be up-
regulated when trypomastigote forms are incubated 
with the extracellular matrix, an obligatory step be-
fore host-cell invasion and differentiation of trypo-
mastigote into amastigote forms (13). The specific 
role of PPDK in EVs secreted by this patient remains 
to be determined.
Among the 19 human proteins uniquely identi-
fied in EVs from the patient with chronic Chagas 
disease before treatment, the mannan binding lectin 
serine protease 2 (MASP2) is worth highlighting. A re-
cent study with human samples showed that MASP2 
gene polymorphisms and MASP2 levels are associ-
ated with high risk for chronic Chagas disease cardio-
myopathy (14). Furthermore, mannose-binding lec-
tin, which activates complement on T. cruzi through 
MASP2, has been related to a decrease in blood and 
tissue parasite load and in myocarditis and cardiac 
fibrosis in experimental T. cruzi infection (15). In this 
study, mRNA levels of collagen-1 and -6 increased in 
the infected animals’ hearts (15). These results could 
support our findings because collagen α-1 is one of 
the proteins identified exclusively in EVs before pa-
tient treatment (Table 2).
Another important observation is the identi-
fication of a higher number of human proteins in 
patient-derived EVs than in the 2 healthy donor–de-
rived EV samples (Figure 2; Appendix). Of the total 
proteins identified, in which statistical analysis was 
feasible, 4 were significantly upregulated in patient-
derived EVs before treatment, particularly for the 
proteins complement C1s subcomponent, isoform 
CRA_b, FLJ00385 protein, and cDNA FLJ75416 (Ap-
pendix). Complement C1s subcomponent recently 
Figure 1. Isolation and characterization of plasma-derived EVs. A) Schematic diagram of the isolation and characterization of EVs 
derived from plasma samples. The details of each step are explained in The Study section. B) EVs were characterized by BBA using the 
classical EV markers CD5L, CD9, and CD63. C) NTA of SEC fractions F7–10. BBA, bead-based assay; EV, extracellular vesicle; LC-
MS/MS, liquid chromatography–tandem mass spectrometry; MFI, median fluorescence intensity; NTA, nanoparticle tracking analysis; 
SEC, size-exclusion chromatography.
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was identified among the 6 upregulated EV bio-
markers with potential for clinical applications in 
myocardial infarction (3).
Conclusions
Proteins associated with EVs secreted by T. cru-
zi have been identified in the conditioned medi-
um of different parasite stages (11–13) but not in 
biofluids from Chagas disease patients. We described 
the proteomic profiling of plasma-derived EVs pu-
rified directly from a heart transplant patient with 
chronic Chagas disease who exhibited reactivation 
after immunosuppression. We identified human and 
parasite proteins present or upregulated in plasma-
derived EVs from a chronic Chagas disease patient 
before chemotherapy and that are absent or down-
regulated after treatment. We thus hypothesize that 
EV proteins released by the host or parasite during 
infection might be potential biomarker candidates 
for evaluating therapeutic response and disease out-
come in chronic Chagas disease, independently of 
the immunologic status of patients.
 
Table 2. Trypanosoma cruzi and human proteins identified in plasma-derived EVs from a heart transplant patient with chronic Chagas 
disease before benznidazole chemotherapy but absent after treatment and in healthy donors 











     
 Pyruvate. phosphate dikinase OS = Trypanosoma cruzi  
 marinkellei GN = MOQ_000480 PE = 3 SV = 1 
K2MVM1_TRYCR 2 (0.96) 0 0 0 
Homo sapiens 
     
 Collagen α-1(VI) chain OS = Homo sapiens GN = COL6A1  
 PE = 1 SV = 3 
CO6A1_HUMAN 3 (1.44) 0 0 0 
 Group of Angiopoietin-related protein 6 OS = Homo sapiens  
 GN = ANGPTL6 PE = 1 SV = 1+1 
ANGL6_HUMAN (+1) 3 (1.44) 0 0 0 
 sp|PPIA_HUMAN| sp|PPIA_HUMAN| 3 (1.44) 0 0 0 
 Mannan binding lectin serine protease 2 OS = Homo sapiens 
 GN = MASP2 PE = 1 SV = 4 
MASP2_HUMAN 2 (1.92) 0 0 0 
 Myosin regulatory light chain 12B OS = Homo sapiens 
 GN = MYL12B PE = 1 SV = 2 
ML12B_HUMAN 2 (1.92) 0 0 0 
 Collagen α-2(VI) chain OS = Homo sapiens GN = COL6A2 
 PE = 1 SV = 4 
CO6A2_HUMAN 2 (1.44) 0 0 0 
 Collectin subfamily member 10 (C-type lectin). isoform CRA_a 
 OS = Homo sapiens GN = COLEC10 PE = 4 SV = 1 
tr|A0A024R9J3|A0A02
4R9J3_HUMAN 
2 (1.44) 0 0 0 
 Group of Coagulation factor XIII A chain OS = Homo sapiens 
 GN = F13A1 PE = 1 SV = 4+2 
F13A_HUMAN (+2) 2 (1.44) 0 0 0 
 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
 activation protein. eta polypeptide. isoform CRA_b OS = Homo 
 sapiens GN = YWHAH PE = 3 SV = 1 
tr|A0A024R1K7|A0A02
4R1K7_HUMAN 
2 (1.44) 0 0 0 
 Fibrinogen-like protein 1 OS = Homo sapiens GN = FGL1 
 PE = 1 SV = 3 
FGL1_HUMAN 2 (0.96) 0 0 0 
 Group of L-lactate dehydrogenase A chain OS = Homo 
 sapiens GN = LDHA PE = 1 SV = 2+1 
LDHA_HUMAN (+1) 2 (0.96) 0 0 0 
 Group of Laminin subunit α-2 OS = Homo sapiens 
 GN = LAMA2 PE = 1 SV = 1+1 
A0A087WX80_HUMAN 
(+1) 
2 (0.96) 0 0 0 
 Group of MHC class I antigen (Fragment) OS = Homo sapiens
 GN = HLA-A PE = 3 SV = 1+3 
tr|D2KZ27|D2KZ27_ 
HUMAN (+3) 
2 (0.96) 0 0 0 
 Group of Serum amyloid A protein OS = Homo sapiens 
 GN = SAA1 PE = 1 SV = 1+2 
E9PQD6_HUMAN (+2) 2 (0.96) 0 0 0 
 Group of Transforming growth factor -induced 68kDa 
 isoform 2 (Fragment) OS = Homo sapiens GN = TGFBI 
 PE = 2 SV = 1+1 
tr|A0A0S2Z4K6|A0A0S
2Z4K6_HUMAN (+1) 
2 (0.96) 0 0 0 
 Heparan sulfate proteoglycan 2 (Perlecan). isoform CRA_b
 OS = Homo sapiens GN = HSPG2 PE = 4 SV = 1 
tr|A0A024RAB6|A0A02
4RAB6_HUMAN 
2 (0.96) 0 0 0 
 Neurogenic locus notch homologue protein 3 OS = Homo 
 sapiens GN = NOTCH3 PE = 1 SV = 2 
NOTC3_HUMAN 2 (0.96) 0 0 0 
 V1–16 protein (Fragment) OS = Homo sapiens GN = V1–16 
 PE = 4 SV = 1 
tr|Q5NV81|Q5NV81_ 
HUMAN 
2 (2.88) 0 0 0 
 Rheumatoid factor RF-ET6 (Fragment) OS = Homo sapiens 
 PE = 2 SV = 1 
tr|A2J1N5|A2J1N5_ 
HUMAN 
2 (5.29) 0 0 0 
*BZN, benznidazole; ChD, Chagas disease. 
†All proteins were identified by at least 2 unique peptides. A unique peptide is defined as a peptide found only in >1 protein members of the same protein 
family of a certain proteome. 
‡Normalized total spectrum count values are indicated in parenthesis. Complete mass spectrometry proteomic data have been deposited to the 
ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the PRoteomics IDEntifications Database (PRIDE, 
https://www.ebi.ac.uk/pride/) partner repository, with the dataset identifier PXD014668 and 10.6019/PXD014668. 
 
However, our results should be interpreted 
with caution because they represent a single clini-
cal case. Further research is needed to validate and 
provide stronger evidence that circulating EVs in 
patients with chronic Chagas disease can serve as 
biomarkers in disease progression and early as-
sessment of therapeutic outcomes. Moreover, the 
future incorporation of such validated biomark-
ers in a point-of-care device could help in the de-
tection of very low parasites in circulation, par-
ticularly when concentrations are below the PCR 
detection level (2).
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